Literature DB >> 21787822

Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Shabir A Madhi1, Avy Violari, Keith P Klugman, Gina Lin, James A McIntyre, Anne von Gottberg, Patrick Jean-Philippe, Mark F Cotton, Peter Adrian.   

Abstract

BACKGROUND: Heightened immunogenicity, measured one month after the primary series of pneumococcal conjugate vaccine (PCV), in African children was previously hypothesized to be due to increased rates of nasopharyngeal pneumococcal colonization during early infancy.
METHODS: We analyzed the effect of selected vaccine-serotype (6B, 19F and 23F) nasopharyngeal colonization prior to the first PCV dose or when colonized for the first time prior to the second or third (2nd/3rd) PCV dose on serotype quantitative and qualitative antibody responses.
RESULTS: Colonization prior to receiving the first PCV was associated with lower geometric mean antibody concentrations (GMCs) one month after the third dose of PCV and six months later to the colonizing-serotype. Colonized infants also had lower geometric mean titers (GMTs) on opsonophagocytosis activity assay (OPA) and a lower proportion had titers ≥ 8 against the colonizing serotypes (19F and 23F) post vaccination. Colonization occurring only prior to the 2nd/3rdPCV dose was also associated with lower GMCs and OPA GMTs to the colonizing-serotype. The effect of colonization with serotypes 19F and 23F prior to PCV vaccination had a greater effect on a lower proportion of colonized infants having OPA titers ≥ 8 than the effect of colonization on the lower proportion with antibody ≥ 0.35 μg/ml.
CONCLUSION: Infant nasopharyngeal colonization at any stage before completing the primary series of PCV vaccination was associated with inferior quantitative and qualitative antibody responses to the colonizing-serotype.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21787822      PMCID: PMC3167924          DOI: 10.1016/j.vaccine.2011.07.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Authors:  F T Cutts; S M A Zaman; G Enwere; S Jaffar; O S Levine; J B Okoko; C Oluwalana; A Vaughan; S K Obaro; A Leach; K P McAdam; E Biney; M Saaka; U Onwuchekwa; F Yallop; N F Pierce; B M Greenwood; R A Adegbola
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

2.  Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

Authors:  Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

3.  Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial.

Authors:  Katherine L O'Brien; Eugene V Millar; Elizabeth R Zell; Melinda Bronsdon; Robert Weatherholtz; Raymond Reid; Jocelyn Becenti; Sheri Kvamme; Cynthia G Whitney; Mathuram Santosham
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

4.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

5.  Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Authors:  Rochelle Lacapa; Sandra J Bliss; Francene Larzelere-Hinton; Kathryn J Eagle; Debra J McGinty; Alan J Parkinson; Mathuram Santosham; Mariddie J Craig; Katherine L O'Brien
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

6.  Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women.

Authors:  C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

7.  Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger
Journal:  Vaccine       Date:  2007-02-21       Impact factor: 3.641

8.  Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.

Authors:  Katherine L O'Brien; Jennifer Moisi; Lawrence H Moulton; Dace Madore; Angelia Eick; Ray Reid; Robert Weatherholtz; Eugene Millar; Diana Hu; Jill Hackell; Robert Kohberger; George Siber; Mathuram Santosham
Journal:  J Infect Dis       Date:  2007-05-24       Impact factor: 5.226

9.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

10.  Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood.

Authors:  Penny Salt; Carly Banner; Sarah Oh; Ly-mee Yu; Susan Lewis; Dingxin Pan; David Griffiths; Berne Ferry; Andrew Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-03-07
View more
  8 in total

1.  Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.

Authors:  Morven S Edwards; Heidi J Lane; Sharon L Hillier; Marcia A Rench; Carol J Baker
Journal:  Vaccine       Date:  2012-04-24       Impact factor: 3.641

Review 2.  Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.

Authors:  Michael E Pichichero
Journal:  Expert Rev Vaccines       Date:  2017-12       Impact factor: 5.217

3.  Blood stream infection is associated with altered heptavalent pneumococcal conjugate vaccine immune responses in very low birth weight infants.

Authors:  J L Wynn; L Li; C M Cotten; D L Phelps; S Shankaran; R N Goldberg; W A Carlo; K Van Meurs; A Das; B R Vohr; R D Higgins; B J Stoll; C T D'Angio
Journal:  J Perinatol       Date:  2013-01-31       Impact factor: 2.521

4.  Cohort profile: The study of respiratory pathogens in Andean children.

Authors:  Carlos G Grijalva; Marie R Griffin; Kathryn M Edwards; John V Williams; Ana I Gil; Héctor Verastegui; Stella M Hartinger; Jorge E Vidal; Keith P Klugman; Claudio F Lanata
Journal:  Int J Epidemiol       Date:  2013-06-14       Impact factor: 7.196

5.  Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.

Authors:  Alassane Dicko; Olumuyiwa O Odusanya; Abdoulbaki I Diallo; Gaoussou Santara; Amadou Barry; Amagana Dolo; Aminata Diallo; Yetunde A Kuyinu; Omolara A Kehinde; Nancy François; Dorota Borys; Juan P Yarzabal; Marta Moreira; Lode Schuerman
Journal:  BMC Public Health       Date:  2011-11-23       Impact factor: 3.295

6.  10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers.

Authors:  D M Muema; E W Nduati; M Uyoga; M Bashraheil; J A G Scott; L L Hammitt; B C Urban
Journal:  Clin Exp Immunol       Date:  2015-06-10       Impact factor: 4.330

7.  Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.

Authors:  John Ojal; Laura L Hammitt; John Gaitho; J Anthony G Scott; David Goldblatt
Journal:  Vaccine       Date:  2017-07-21       Impact factor: 3.641

8.  Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Authors:  Amanda Jane Leach; Edward Kim Mulholland; Mathuram Santosham; Paul John Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Mark D Chatfield; Victor M Oguoma; Paul Licciardi; Sue Skull; Ross Andrews; Jonathan Carapetis; Joseph McDonnell; Vicki Krause; Peter Stanley Morris
Journal:  Vaccine X       Date:  2021-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.